NCT01147666 - Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis | Biotech Hunter

Enrollment

161

Participants

Timeline

Start Date

May 17, 2010

Primary Completion Date

October 15, 2012

Study Completion Date

October 15, 2012

Conditions

End Stage Renal DiseaseAnemia

Interventions

DRUG

Roxadustat

Roxadustat will be administered per dose and schedule specified in the arms.

DRUG

Epoetin Alfa

Epoetin Alfa will be administered per dose and schedule specified in the arms.

OTHER

Placebo

Placebo matching to roxadustat will be administered per schedule specified in the arm.

Trial Locations (25)

Unknown

Tempe

Pine Bluff

Azusa

Los Angeles

Northridge

Ontario

Paramount

Yuba City

Miami

Pembroke Pines

Honolulu

Louisville

Detroit

Kansas City

Paterson

New York

Rosedale

Williamsville

Toledo

Orangeburg

Arlington

Fort Worth

Houston

San Antonio

Fairfax